Dr Hannah Wardill

NHMRC Externally-Funded Research Fellow B

School of Biomedicine

Faculty of Health and Medical Sciences

Eligible to supervise Masters and PhD - email supervisor to discuss availability.

Dr Hannah Wardill is a dynamic early career researcher with a simple mission: prevent the long-term physical, emotional and economic disadvantages of cancer and its treatment by developing innovative supportive care solutions tailored to meet the unique needs of the patient.

After completing her PhD at the University of Adelaide and receiving Dean's Commendation for Doctoral Research Excellence, Hannah secured an NHMRC CJ Martin Biomedical training fellowship allowing her to relocate to the University of Groningen, the Netherlands. Here she led a program of research dedicated to understanding how the microbiota contributes to chemotherapy-induced diarrhea, graft versus host disease (GvHD) and blood stream infection in both paediatric and adult cancers.

Hannah has recently returned back to Australia and now leads the Supportive Oncology Research Group - a multidisciplinary group dedicated to improving the health and wellbeing of people affected by cancer. Since forming her group, Hannah has attracted >$2M in competitive funding, including $1.49M from the Medical Research Future Fund to investigate the efficacy of medicinal cannabis in controlling the side effects of chemotherapy, as well as funding from Cancer Australia, the Leukaemia Foundation and The Hospital Research Foundation.

In recognition of her contribution to the field of supportive cancer care, Hannah has been awarded the Multinational Association for Supportive Care in Cancer International Investigator Award, was named the South Australian Young Achiever, the Qiagen Microbiome Award winner, South Australian Tall Poppy of the Year and the 40Under40 Award for Social Impact.

Hannah's research is highly patient-centric, and based on a strong foundation of consumer engagement. She represents the University of Adelaide on the Health Translation SA Consumer Engagement Committee and established the Consumer Engagement Committee for the Multinational Association for Supportive Care in Cancer.

My Research
Career
Publications
Grants and Funding
Teaching
Supervision
Professional Activities
Contact

Overview: Dr Wardill completed her PhD at the University of Adelaide, under the guidance of A/Prof Joanne Bowen, Prof Rachel Gibson and Prof Richard Logan, completing her doctoral thesis in 2016. During her PhD she developed and validated the first TLR4 knockout mouse model of irinotecan induced mucositis, and in doing so, clearly demonstrated the impact of innate immune signaling and microbial dysbiosis on mucosal barrier injury and clinical toxicity. She was subsequently recognised for her contribution to the field of supportive oncology, named the 2016 MASCC Young Investigator of the Year and awarded the University Medal for Doctoral Research Excellence. After a short postdoctoral position at the South Australian Health and Medical Research Institute, Hannah established a highly interdisciplinary research team within Adelaide aiming to establish an autologous faecal transplantation service for people with blood cancer. This project has received funding support from two major hospitals across South Australia and has lead to numerous international collaborations across the Netherlands, Germany and the US. Hannah then took up a position at the largest medical centre in the north of the Netherlands where she lead numerous preclinical trials for new supportive care interventions, with Anakinra (IL-1RA) transitioning to clinical trial. In 2020, Hannah returned to Adelaide where she now leads the Supportive Oncology Research Group at SAHMRI.

National and international standing: Hannah has been a member of the Multinational Association for Supportive Care in Cancer and the Mucositis Research Group from 2013-present. She has presented at 9 consecutive meetings, with her work highlighted by plenary speakers. In 2017, Hannah was invited to act as section co-head for the update of the clinical practice guidelines for mucositis management and risk prediction (Wardill et al., 2019 JSCC). This involved leading a group of international scientists and clinicians to conduct a through review of the literature and the preparation of clinical practice guidelines. Hannah is the Vice-Chair of the MASCC Mucositis Study Group, leads the society's social media strategy and is an active committee member for the newly formed Consumer Engagement Group. Nationally, Hannah is a member of the Scientific Advisory Committee for the Primary Care Collaborative Cancer Clinical Trials Group (PC4), Chair for the Gut Dysfunction Node of the Cancer Symptoms Trials Group (Palliative Care Clinical Trials Collaborative) - each of which are funded by Cancer Australia. Hannah is also the Supportive Care / Survivorship lead for the South Australian Comprehensive Cancer Consortium (SACCC).

Community engagement: As a 2021 Superstar of STEM and South Australian Tall Poppy, Hannah has a strong commitment to engaging the general community with scientific discovery. She has received significant media training through outlets such as Fresh Science and Thinkwell, which enable her to effectively communicate complex scientific research with lay audiences of many ages. This has been demonstrated through her involvement with Science Alive, an interactive event for children held yearly, and her volunteer work with Lynch Syndrome Australia. Hannah also founded and maintains a blog pooisnottaboo.com which aims to provide scientifically accurate, yet exciting content about the advances in our understanding of the gut microbiome. Connect with her on Twitter @hannahrwardill @SuppOncRG!

Contribution to field of research: Dr Wardill has an impressive publication track record for someone of her career stage, with numerous peer-reviewed research publications in top-tier oncology (e.g. Molecular Cancer Therapeutics) and gastroenterology journals (e.g. Gut). These publication include invited reviews, opinion pieces, mechanistic hypotheses, primary research (preclinical and clinical) and clinical practice guidelines. Hannah has also been invited to contribute to publicly available platforms such as eHospice, The Conversation and Future Oncology, as well as being invited to contribute to a book chapter.

ORCID: 0000-0002-6613-3661

Active projects for prospective collaborators and students:

Project 1

Title: Establshing a faecal microbiome transplantation protocol for the prevention of GvHD in allo-SCT recipients.

Description: Graft versus host disease (GvHD) is the largest cause of treatment-related mortality in people with blood cancer. Damage to the intestinal barrier and associated disruption of the microbiome are key risk factors for GvHD severity and associated mortality. This project involves 1) a pilot study to assess the feasibility of delivering autologous faecal microbiome translation to stem cell transplantation recipients, and 2) development of a preclinical murine model of GvHD to evaluate autologous and donor faecal transplant efficacy.

Location: SAHMRI / Royal Adelaide Hospital.

Available for: Honours / PhD

Project 2

Title: Personalised risk evaluation during cancer therapy (PREDiCT)

Description: The outcomes of cancer therapy are highly heterogenous, with little understanding of the targetable factors that determine both efficacy and toxicity outcomes. This project aims to develop a comprehensive risk evaluation tool to predict an individual's response to treatment based on their own unique microbial composition, immune function, genetics and demographic variables (diet, medication, age, sex, etc). We recruit patients undergoing systemic anticancer therapy, for any cancer diagnosis, across three major sites across South Australia.

Location: Helen Mayo Building and SAHMRI.

Available for: Honours / PhD

Project 3

Title: Neuroinflammation and its contribution to neurological disease in survivors of childhood cancer

Description: Survivors of childhood cancer are at risk of long-term neurological disease including psychosocial changes, cognitive impairment, accelerated/premature neurodegeneration and cancer. This project aims to understand the molecular determinants of chronic neurological disease and develop translational prognostic methods.

Location: Helen Mayo Building and SAHMRI.

Available for: Honours / PhD

Project 4

Title: The CANCAN trial

Description: An MRFF-funded trial investigating the use of medicinal cannabis to control the side effects of chemotherapy used to treat advanced cancer.

Location: SAHMR.

Available for: Masters / PhD

Appointments

Date	Position	Institution name
2020 - 2020	Postdoctoral Researcher	The University of Groningen (University Medical Centre Groningen)
2018 - 2022	NHMRC CJ Martin Biomedical Research Fellow	The University of Adelaide and The University of Groningen
2017 - ongoing	UniSA Online Tutor	The University of South Australia
2016 - 2017	Postdoctoral Researcher	South Australian Health and Medical Research Institute

Awards and Achievements

Date	Type	Title	Institution Name	Country	Amount
2021	Award	SA Tall poppy of the Year	Australian Institute of Policy and Science	Australia
2020	Award	Executive Dean's Early Career Researcher Award	The University of Adelaide	Australia
2020	Award	40 Under 40 Award for Innovation and Entrepreneurship	In Daily / Soltice Media	Australia
2020	Award	40 Under 40 Award for Social Impact	In Daily / Solstice Media	Australia
2020	Award	MedTech's Got Talent 2020 Winner	MedTech Actuator	Australia	$10,000
2019	Award	Women's Research Excellence Award Winner	The University of Adelaide	Australia	5000
2018	Award	Qiagen International Microbiome Award Winner 2019	Qiagen	Germany	79,116 USD
2018	Award	Future Science Group ECR Award	Future Science Group	United Kingdom
2018	Award	L'Oreal Women in Science (Finalist)	L'Oreal	Australia
2017	Award	SAHMRI Early Career Research Prize
2017	Award	SAHMRI Shark Tank Prize
2017	Award	South Australia Science Excellence Awards (PhD Excellence) Finalist	South Australian Department of Industry and Skills	Australia
2017	Award	SA Science Excellence Awards Finalist (PhD Excellence)
2017	Award	You Can Innovate Award Finalist
2017	Award	University Medal for Doctoral Research Excellence	University of Adelaide	Australia
2016	Award	Dean's Commendation for Research Thesis Excellence
2016	Award	Nature Reviews Gastroenterology & Hepatology ‘Best Oral Presentation’
2016	Award	MASCC/ISOO Young Investigator of the Year
2016	Award	Channel 9 Young Achiever Award; Science and Technology
2016	Award	Fresh Science SA Winner
2015	Award	Australian Society for Medical Research Campion-Ma-Playoust Memorial Award
2015	Award	Florey Medical Research Foundation Prize; Best Poster
2015	Achievement	Channel 9 Young Achiever Award; Science and Technology Runner Up
2015	Scholarship	Florey Medical Research Foundation Doctor Chun Chung and Madam So Sau Lam Memorial Postgraduate Award
2014	Award	Florey Medical Research Foundation Prize; Best Poster
2014	Achievement	Channel 9 Young Achiever Award; Science and Technology Finalist
2013	Scholarship	Australian Postgraduate Award
2012	Award	Highest Honours Grade; School of Medicine
2012	Award	Bachelor of Health Sciences, Executive Dean's Certificate of Merit
2012	Award	Best Honours Poster Presentation
2012	Recognition	Mace Bearer
2011	Award	Highest Aggregate Grade in Major: Physiology (School of Medicine)
2011	Award	Highest Aggregate Grade in Major: Anatomical Sciences (School of Medicine)
2011	Award	Highest Aggregate Grade in Major: Reproductive Biology (School of Medicine)

Education

Date	Institution name	Country	Title
2013 - 2016	University of Adelaide	Australia	PhD, Medicine
2012 - 2012	University of Adelaide	Australia	Bachelor of Health Sciences (Honours)
2009 - 2011	University of Adelaide	Australia	Bachelor of Health Sciences

Research Interests

Cancer Cell Biology Cancer Therapy Gastroenterology and Hepatology

Journals

Year	Citation
2022	Bowen, J., & Wardill, H. (2022). The science of mucositis. Supportive Care in Cancer, 30(4), 2915-2917. DOI
2022	Wardill, H. R., Chan, R. J., Chan, A., Keefe, D., Costello, S. P., & Hart, N. H. (2022). Dual contribution of the gut microbiome to immunotherapy efficacy and toxicity: supportive care implications and recommendations. Supportive Care in Cancer, 5 pages. DOI
2022	Pagani, I. S., Poudel, G., & Wardill, H. R. (2022). A Gut Instinct on Leukaemia: A New Mechanistic Hypothesis for Microbiota‐Immune Crosstalk in Disease Progression and Relapse. Microorganisms, 10(4), 14 pages. DOI
2022	Wardill, H. R., & Martin, A. M. (2022). Are stressed out goblets cells to blame for functional dyspepsia symptoms?. Brain, Behavior, and Immunity, 103, 61-62. DOI
2021	da Silva Ferreira, A. R., van der Aa, S. A. J., Wehkamp, T., Wardill, H. R., ten Klooster, J. P., Garssen, J., . . . van Bergenhenegouwen, J. (2021). Development of a self-limiting model of methotrexate-induced mucositis reinforces butyrate as a potential therapy. Scientific Reports, 11(1), 22911-1-22911-11. DOI
2021	Secombe, K. R., Crame, E. E., Tam, S. Y. J., Wardill, H. R., Gibson, R. J., Coller, J. K., & Bowen, J. M. (2021). Intestinal toll-like receptor 4 knockout alters the functional capacity of the gut microbiome following irinotecan treatment.. Cancer Chemother Pharmacol, 89(2), 275-281. DOI
2021	Bruning, E. E., Coller, J. K., Wardill, H. R., & Bowen, J. M. (2021). Site-specific contribution of Toll-like receptor 4 to intestinal homeostasis and inflammatory disease. Journal of Cellular Physiology, 236(2), 877-888. DOI Scopus3 WoS2 Europe PMC2
2021	da Silva Ferreira, A. R., Wardill, H. R., Havinga, R., Tissing, W. J. E., & Harmsen, H. J. M. (2021). Prophylactic treatment with vitamins C and B2 for methotrexate-induced gastrointestinal mucositis. Biomolecules, 11(1), 1-15. DOI Scopus1
2021	Wardill, H. R., de Mooij, C. E. M., da Silva Ferreira, A. R., van de Peppel, I. P., Havinga, R., Harmsen, H. J. M., . . . Blijlevens, N. M. A. (2021). Translational model of melphalan-induced gut toxicity reveals drug-host-microbe interactions that drive tissue injury and fever. Cancer Chemotherapy and Pharmacology, 88(2), 173-188. DOI Scopus4 WoS5 Europe PMC1
2021	Wardill, H. R., van der Aa, S. A. R., da Silva Ferreira, A. R., Havinga, R., Tissing, W. J. E., & Harmsen, H. J. M. (2021). Antibiotic-induced disruption of the microbiome exacerbates chemotherapy-induced diarrhoea and can be mitigated with autologous faecal microbiota transplantation. European Journal of Cancer, 153, 27-39. DOI Scopus2 WoS3 Europe PMC2
2021	Gheorghe, C. E., Ritz, N. L., Martin, J. A., Wardill, H. R., Cryan, J. F., & Clarke, G. (2021). Investigating causality with fecal microbiota transplantation in rodents: applications, recommendations and pitfalls.. Gut Microbes, 13(1), 1-51. DOI Scopus8 WoS7 Europe PMC5
2021	Secombe, K. R., Al-Qadami, G. H., Subramaniam, C. B., Bowen, J. M., Scott, J., Van Sebille, Y. Z. A., . . . Wardill, H. R. (2021). Guidelines for reporting on animal fecal transplantation (GRAFT) studies: recommendations from a systematic review of murine transplantation protocols. Gut Microbes, 13(1), 1979878-1-1979878-15. DOI Scopus5 WoS5 Europe PMC3
2021	Crame, E. E., Bowen, J. M., Secombe, K. R., Coller, J. K., François, M., Leifert, W., & Wardill, H. R. (2021). Epithelial-Specific TLR4 Knockout Challenges Current Evidence of TLR4 Homeostatic Control of Gut Permeability. Inflammatory Intestinal Diseases, 6(4), 1-11. DOI Scopus1
2021	da Silva Ferreira, A. R., Märtson, A. -G., de Boer, A., Wardill, H. R., Alffenaar, J. -W., Harmsen, H. J. M., & Tissing, W. J. E. (2021). Does chemotherapy-induced gastrointestinal mucositis affect the bioavailability and efficacy of anti-infective drugs?. Biomedicines, 9(10), 1389-1-1389-13. DOI
2020	Elad, S., Cheng, K. K. F., Lalla, R. V., Yarom, N., Hong, C., Logan, R. M., . . . Zur, E. (2020). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 126(19), 4423-4431. DOI Scopus75 WoS63 Europe PMC33
2020	Wardill, H. R., da Silva Ferreira, A. R., Lichtenberg Cloo, S., Havinga, R., Harmsen, H. J. M., Vermeij, W. P., & Tissing, W. J. E. (2020). Pre-therapy fasting slows epithelial turnover and modulates the microbiota but fails to mitigate methotrexate-induced gastrointestinal mucositis. Gut Microbes, 12(1), e1809332-1-e1809332-10. DOI Scopus4 WoS4 Europe PMC3
2020	Wardill, H. R., Sonis, S. T., Blijlevens, N. M. A., Van Sebille, Y. Z. A., Ciorba, M. A., Loeffen, E. A. H., . . . Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). (2020). Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action. Support Care Cancer, 28(11), 5059-5073. DOI Scopus10 WoS7 Europe PMC1
2020	Subramaniam, C. B., Bowen, J. M., Gladman, M. A., Lustberg, M. B., Mayo, S. J., & Wardill, H. R. (2020). The microbiota-gut-brain axis: an emerging therapeutic target in chemotherapy-induced cognitive impairment. Neuroscience and Biobehavioral Reviews, 116, 470-479. DOI Scopus10 WoS9 Europe PMC6
2020	da Silva Ferreira, A. R., Wardill, H. R., Tissing, W. J. E., & Harmsen, H. J. M. (2020). Pitfalls and novel experimental approaches to optimize microbial interventions for chemotherapy-induced gastrointestinal mucositis. Current Opinion in Supportive and Palliative Care, 14(2), 127-134. DOI Scopus5 WoS4 Europe PMC2
2019	Secombe, K. R., Coller, J. K., Gibson, R. J., Wardill, H. R., & Bowen, J. M. (2019). The bidirectional interaction of the gut microbiome and the innate immune system: Implications for chemotherapy‐induced gastrointestinal toxicity. International Journal of Cancer, 144(10), 2365-2376. DOI Scopus23 WoS23 Europe PMC14
2019	Dmochowska, N., Tieu, W., Keller, M. D., Wardill, H. R., Mavrangelos, C., Campaniello, M. A., . . . Hughes, P. A. (2019). Immuno-PET of Innate Immune Markers CD11b and IL-1β Detects Inflammation in Murine Colitis. Journal of nuclear medicine : Official publication, Society of Nuclear Medicine, 60(6), 858-863. DOI Scopus16 WoS15 Europe PMC11
2019	Wardill, H. R., Choo, J. M., Dmochowska, N., Mavrangelos, C., Campaniello, M. A., Bowen, J. M., . . . Hughes, P. A. (2019). Acute colitis drives tolerance by persistently altering the epithelial barrier and innate and adaptive immunity. Inflammatory Bowel Diseases, 25(7), 1196-1207. DOI Scopus7 WoS6 Europe PMC6
2019	Wardill, H., Secombe, K., Bryant, R., Hazenberg, M., & Costello, S. (2019). Adjunctive fecal microbiota transplantation in supportive oncology: emerging indications and considerations in immunocompromised patients. EBioMedicine, 44, 730-740. DOI Scopus28 WoS27 Europe PMC16
2019	Wardill, H., Tissing, W., Kissow, H., & Stringer, A. (2019). Animal models of mucositis: critical tools for advancing pathobiological understanding and identifying therapeutic targets. Current Opinion in Supportive and Palliative Care, 13(2), 119-133. DOI Scopus6 WoS7 Europe PMC5
2019	Van Sebille, Y. Z., Gibson, R. J., Wardill, H. R., Carney, T. J., & Bowen, J. M. (2019). Use of zebrafish to model chemotherapy and targeted therapy gastrointestinal toxicity.. Experimental biology and medicine (Maywood, N.J.), 244(14), 1178-1185. DOI Scopus7 WoS7 Europe PMC3
2019	Bowen, J. M., Gibson, R. J., Coller, J. K., Blijlevens, N., Bossi, P., Al-Dasooqi, N., . . . Elad, S. (2019). Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines. Supportive Care in Cancer, 27(10), 4011-4022. DOI Scopus26 WoS28 Europe PMC14
2019	Bowen, J., Al-Dasooqi, N., Bossi, P., Wardill, H., Van Sebille, Y., Al-Azri, A., . . . Elad, S. (2019). The pathogenesis of mucositis: updated perspectives and emerging targets. Supportive Care in Cancer, 27(10), 4023-4033. DOI Scopus53 WoS46 Europe PMC28
2019	Wardill, H. (2019). Early career interview: Hannah Wardill. Future Science OA, 5(4). DOI Scopus1
2018	Gibson, R. J., Van Sebille, Y. Z. A., Wardill, H. R., Wignall, A., Shirren, J., Ball, I. A., . . . Bowen, J. M. (2018). Selective MMP inhibition, using AZD3342, to reduce gastrointestinal toxicity and enhance chemoefficacy in a rat model. Chemotherapy, 63(5), 284-292. DOI Scopus4 WoS4 Europe PMC1
2018	Wardill, H., Van Sebille, Y., Ciorba, M., & Bowen, J. (2018). Prophylactic probiotics for cancer therapy-induced diarrhoea: A meta-analysis. Current Opinion in Supportive and Palliative Care, 12(2), 187-197. DOI Scopus28 WoS31 Europe PMC19
2018	Khan, S., Wardill, H., & Bowen, J. (2018). Role of toll-like receptor 4 (TLR4)-mediated interleukin-6 (IL-6) production in chemotherapy-induced mucositis. Cancer Chemotherapy and Pharmacology, 82(1), 31-37. DOI Scopus6 WoS5 Europe PMC1
2018	Hofma, B., Wardill, H., Mavrangelos, C., Campaniello, M., Dimasi, D., Bowen, J., . . . Hughes, P. (2018). Colonic migrating motor complexes are inhibited in acute tri-nitro benzene sulphonic acid colitis. PLoS ONE, 13(6), e0199394-1-e0199394-15. DOI Scopus11 WoS10 Europe PMC8
2018	Dmochowska, N., Wardill, H., & Hughes, P. (2018). Advances in imaging specific mediators of inflammatory bowel disease. International Journal of Molecular Sciences, 19(9), 2471-1-2471-13. DOI Scopus14 WoS14 Europe PMC11
2018	Van Sebille, Y., Gibson, R., Wardill, H., Ball, I., Keefe, D., & Bowen, J. (2018). Dacomitinib-induced diarrhea: Targeting chloride secretion with crofelemer. International Journal of Cancer, 142(2), 369-380. DOI Scopus6 WoS6 Europe PMC5
2017	Bowen, J., & Wardill, H. (2017). Advances in the understanding and management of mucositis during stem cell transplantation. Current Opinion in Supportive and Palliative Care, 11(4), 341-346. DOI Scopus17 WoS15 Europe PMC10
2017	Van Sebille, Y., Gibson, R., Wardill, H., Secombe, K., Ball, I., Keefe, D., . . . Bowen, J. (2017). Dacomitinib-induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats. International Journal of Cancer, 140(12), 2820-2829. DOI Scopus17 WoS14 Europe PMC12
2017	Wardill, H., & Tissing, W. (2017). Determining risk of severe gastrointestinal toxicity based on pretreatment gut microbial community in patients receiving cancer treatment: a new predictive strategy in the quest for personalized cancer medicine. Current Opinion in Supportive and Palliative Care, 11(2), 125-132. DOI Scopus18 WoS18 Europe PMC11
2017	Coller, J., Bowen, J., Ball, I., Wardill, H., Van Sebille, Y., Stansborough, R., . . . Gibson, R. (2017). Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report. Cancer Chemotherapy and Pharmacology, 79(2), 431-434. DOI Scopus6 WoS5 Europe PMC3
2017	Wardill, H., Bowen, J., Van Sebille, Y., & Gibson, R. (2017). Routine assessment of the gut microbiome to promote preclinical research reproducibility and transparency. Gut, 66(10), 1869-1871. DOI Scopus3 WoS3 Europe PMC2
2016	Wardill, H., Logan, R., Bowen, J., Van Sebille, Y., & Gibson, R. (2016). Tight junction defects are seen in the buccal mucosa of patients receiving standard dose chemotherapy for cancer. Supportive Care in Cancer, 24(4), 1779-1788. DOI Scopus13 WoS13 Europe PMC7
2016	Gibson, R., Coller, J., Wardill, H., Hutchinson, M., Smid, S., & Bowen, J. (2016). Chemotherapy-induced gut toxicity and pain: involvement of TLRs. Supportive Care in Cancer, 24(5), 2251-2258. DOI Scopus17 WoS16 Europe PMC6
2016	Wardill, H., Gibson, R., Van Sebille, Y., Secombe, K., Logan, R., & Bowen, J. (2016). A novel in vitro platform for the study of SN38-induced mucosal damage and the development of Toll-like receptor 4-targeted therapeutic options. Experimental Biology and Medicine, 241(13), 1386-1394. DOI Scopus7 WoS7 Europe PMC5
2016	Van Sebille, Y., Gibson, R., Wardill, H., & Bowen, J. (2016). Gastrointestinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Current Opinion in Supportive and Palliative Care, 10(2), 152-156. DOI Scopus6 WoS6 Europe PMC5
2016	Wardill, H., Gibson, R., Van Sebille, Y., Secombe, K., Coller, J., White, I., . . . Bowen, J. (2016). Irinotecan-induced gastrointestinal dysfunction and pain are mediated by common TLR4-dependent mechanisms. Molecular Cancer Therapeutics, 15(6), 1376-1386. DOI Scopus65 WoS62 Europe PMC35
2016	Wardill, H., Mander, K., Van Sebille, Y., Gibson, R., Logan, R., Bowen, J., & Sonis, S. (2016). Cytokine-mediated blood brain barrier disruption as a conduit for cancer/chemotherapy-associated neurotoxicity and cognitive dysfunction. International Journal of Cancer, 139(12), 2635-2645. DOI Scopus66 WoS57 Europe PMC29
2016	Wardill, H., Bowen, J., Van Sebille, Y., Secombe, K., Coller, J., Ball, I., . . . Gibson, R. (2016). TLR4-dependent claudin-1 internalization and secretagogue-mediated chloride secretion regulate irinotecan-induced diarrhea. Molecular Cancer Therapeutics, 15(11), 2767-2779. DOI Scopus24 WoS24 Europe PMC12
2015	Wardill, H. R., Logan, R. M., Bowen., & Gibson. (2015). Chemotherapy causes tight junction defects in the oral cavity of patients which co-incide with elevated pro inflammatory cytokines and MMPs. Australian Dent, 60(4).
2015	Wardill, H., Van Sebille, Y., Mander, K., Gibson, R., Logan, R., Bowen, J., & Sonis, S. (2015). Toll-like receptor 4 signaling: a common biological mechanism of regimen-related toxicities an emerging hypothesis for neuropathy and gastrointestinal toxicity. Cancer Treatment Reviews, 41(2), 122-128. DOI Scopus28 WoS27 Europe PMC17
2015	Wardill, H., Van Sebille, Y., Bowen, J., & Gibson, R. (2015). Editorial comment: does gut-derived inflammation enhance pain signaling following chemotherapy in a Toll-like receptor 4-dependent manner?. Current Opinion in Supportive and Palliative Care, 9(2), 155-156. DOI Scopus1 WoS1
2015	Van Sebille, Y., Gibson, R., Wardill, H., & Bowen, J. (2015). ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: chloride secretion as a mechanistic hypothesis. Cancer Treatment Reviews, 41(7), 646-652. DOI Scopus31 WoS31 Europe PMC20
2015	Van Sebille, Y., Stansborough, R., Wardill, H., Bateman, E., Gibson, R., & Keefe, D. (2015). Management of mucositis during chemotherapy: from pathophysiology to pragmatic therapeutics. Current Oncology Reports, 17(11), 50-1-50-8. DOI Scopus44 WoS43 Europe PMC20
2014	Wardill, H., Gibson, R., Logan, R., & Bowen, J. (2014). TLR4/PKC-mediated tight junction modulation: a clinical marker of chemotherapy-induced gut toxicity?. International Journal of Cancer, 135(11), 2483-2492. DOI Scopus25 WoS24 Europe PMC12
2014	Al-Dasooqi, N., Wardill, H., & Gibson, R. (2014). Gastrointestinal mucositis: the role of MMP-tight junction interactions in tissue injury. Pathology and Oncology Research, 20(3), 485-491. DOI Scopus17 WoS16 Europe PMC10
2014	Wardill, H. R., Bowen, J. M., & Gibson, R. J. (2014). New pharmacotherapy options for chemotherapy-induced alimentary mucositis. Expert Opinion on Biological Therapy, 14(3), 347-354. DOI Scopus12 WoS12 Europe PMC7
2014	Wardill, H., Bowen, J., Al-Dasooqi, N., Sultani, M., Bateman, E., Stansborough, R., . . . Gibson, R. (2014). Irinotecan disrupts tight junction proteins within the gut: implications for chemotherapy-induced gut toxicity. Cancer Biology and Therapy, 15(2), 236-244. DOI Scopus47 WoS45 Europe PMC32
2013	Wardill, H., & Gibson, R. (2013). Detecting gut injury during chemotherapy: is a breath test the answer?. Future Oncology, 9(9), 1245-1247. DOI
2013	Wardill, H., & Bowen, J. (2013). Chemotherapy-induced mucosal barrier dysfunction: an updated review on the role of intestinal tight junctions. Current Opinion in Supportive and Palliative Care, 7(2), 155-161. DOI Scopus42 WoS43 Europe PMC29
2013	Wardill, H., Bowen, J., & Gibson, R. (2013). Biomarkers of small intestinal mucosal damage induced by chemotherapy: an emerging role for the 13C sucrose breath test. The Journal of Supportive Oncology, 11(2), 61-67. DOI Scopus10 Europe PMC7
2012	Wardill, H., Bowen, J., & Gibson, R. (2012). Chemotherapy-induced gut toxicity: are alterations to intestinal tight junctions pivotal?. Cancer Chemotherapy and Pharmacology, 70(5), 627-635. DOI Scopus29 WoS30 Europe PMC20
	Wardill, H. R., Mooij, C. E. M. D., Ferreira, A. R. D. S., Peppel, I. P. V. D., Havinga, R., Harmsen, H. J. M., . . . Blijlevens, N. M. A. (n.d.). Host Microbiome Dictates Infection Risk after Chemotherapy Revealing New Avenues for Antibiotic Stewardship in Oncology. DOI

Conference Papers

Year	Citation
2021	Al-Qadami, G., Bowen, J., Van Sebille, Y., Wardill, H., Secombe, K., & Le, H. (2021). Pre-treatment gut microbiome and radiotherapy response and toxicities among patients with head and neck cancer. In MASCC/ISOO Annual Meeting.
2021	Subramaniam, C. B., Wardill, H. R. R., Gladman, M. A., & Bowen, J. M. (2021). 5-FU induces acute neurodegeneration followed by persistent neuroinflammation: A new mechanistic hypothesis for the neurological complications of cancer therapy. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 17 (pp. 113). WILEY.
2021	Crame, E., Wardill, H. R., Secombe, K., Coller, J., & Bowen, J. (2021). Intestinal epithelial TLR4 are crucial to chemotherapy toxicity development. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 17 (pp. 110). WILEY.
2021	Secombe, K., Ball, I., Subramaniam, C., Al-Qadami, G., Bowen, J., & Wardill, H. R. (2021). Using patient-reported outcome measures to determine the role of the microbiome in cancer treatment-induced diarrhoea. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 17 (pp. 174-175). WILEY.
2021	Wardill, H. R., De Mooij, C. M. E., van der Velden, W. J. F. M., Harmsen, H. J. M., Tissing, W. J. E., & Blijlevens, N. M. A. (2021). Anakinra is safe in HSCT recipients and reinforces the mucosal barrier to control acute complications of high-dose melphalan: results from the AFFECT-1 (Phase IIA) trial and preclinical efficacy study. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 17 (pp. 115). WILEY.
2018	Secombe, K., Bowen, J., Coller, J., Gibson, R., Stringer, A., Al-Dasooqi, N., . . . Wardill, H. R. (2018). Pre-treatment Blautia abundance regulates chemotherapy-induced gastrointestinal toxicity risk: a pilot study. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 14 (pp. 59). WILEY. WoS1

Conference Items

Year	Citation
2018	Hughes, P., Wardill, H., Dmochowska, N., Mavrangelos, C., Campaniello, M., Bowen, J., . . . Andrews, J. (2018). Proteolytic activation of IL-1 beta impairs epithelial barrier integrity in the ulcerative colitis lumen. Poster session presented at the meeting of Journal of Gastroenterology and Hepatology. Brisbane, Qld: Wiley.
2017	Wardill, H., Dmochowska, N., Campaniello, M., Mavrangelos, C., Bowen, J., Andrews, J., . . . Hughes, P. (2017). Fecal supernatants from active ulcerative colitis patients impair colonic epithelial barrier integrity and activate pelvic mucosal extrinsic afferent nerves. Poster session presented at the meeting of FASEB Journal. Chicago, IL: Federation of American Societies for Experimental Biology.
2017	Secombe, K. R., Ball, I. A., Shirren, J., Wignall, A. D., Wardill, H. R., Van Sebille, Y. Z. A., & Bowen, J. M. (2017). Budesonide Reduces Neratinib-Induced Gastrointestinal Injury and Diarrhoea in Rats. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY. WoS2

Theses

Year Citation

2016 Wardill, H. (2016). Toll-like receptor 4-dependent barrier dysfunction and its impact on irinotecan-induced gut toxicity and pain. (PhD Thesis).

Year	Citation
2016	Wardill, H. (2016). Toll-like receptor 4-dependent barrier dysfunction and its impact on irinotecan-induced gut toxicity and pain. (PhD Thesis).

Year	Source of funding	Position	Amount
2022	The Hospital Research Foundation Research Fellowship	Sole CI	$570,000
2021	Cancer Council Beat Cancer Early Career Fellowship (not accepted due to competing fellowship offers)	Sole CI	$480,000
2021	Neurosurgical Research Foundation	CIB	$50,000
2021	Medical Research Future Fund Emerging Priorities and Consumer Driven Research - Medicinal Cannabis Clinical Trials Grant Opportunity	CIB	$1.487 M
2021	Cancer Australia / Leukaemia Foundation PdCCRS	Sole CI	$183,347
2021	The University of Adelaide, Faculty of Health and Medical Sciences, Infrastructure Grant (Zetasizer Ultra)	CIB	$112,300
2021	The University of Adelaide, Faculty of Health and Medical Sciences, Infrastructure Grant (Ussing Chamber core facility update)	CIE	$29,796
2021	The University of Adelaide, Faculty of Health and Medical Sciences, Emerging Leaders Grant	Sole CI	$40,000
2020	Nutricia (Danone) Research: Evaluating hydrolysed protein diet in tumour bearing model of MTX toxicity.	CIA	$25,000
2020	Onderzoeksproject Stichting Beatrix Kinderziekenhuis (The Beatrix Children’s Hospital Foundation)	CIC	€35,000
2019	MedTech’s Got Talent Winner	CIA	$10,000
2018	Qiagen Microbiome Awards - Developing a predictive algorithm for complications of paediatric cancer treatment.	Sole CI	USD 79,116
2018	The University of Adelaide, Women’s Research Excellence Award	Sole CI	$5,000
2018	The University of Adelaide, Faculty of Health and Medical Sciences, Infrastructure Grant (EVOS Live Cell Imager)	CIB	$90,816
2018	The University of Adelaide, Faculty of Health and Medical Sciences, Infrastructure Grant (Anaerobic Chamber)	CIE	$43,195
2018	NHMRC CJ Martin Biomedical Research Early Career Fellowship	Sole CI	$412,952
2018	Royal Adelaide Hospital Clinical Project Grant	CIA	$43,092 (+$30,000 co-funding)
2018	The Hospital Research Foundation Grant	CIA	$50,000
2017	The University of Adelaide FHMS ECR Project Development Mentorship Grant	CIA	$15,000
2017	The University of Adelaide FHMS Project Development Grant	CIB	$24,293
2017	Commonwealth Scientific and Industrial Research Organisation (CSIRO) ON Prime Program	CIA	$3,600
2017	The University of Adelaide, Faculty of Health and Medical Sciences, Infrastructure Grant (Human Ussing Chamber)	CID	$41,600 (+$30,000 co-funding)
2015 -16	Florey Medical Research Foundation	Sole CI	$10,000
2014 -15	Australian Dental Research Foundation	CIA	$5,200

Undergraduate Teaching

Throughout my postgraduate training and postdoctoral research, I have been actively involved in the teaching, supervision and mentoring of undergraduate and honours students. I have delivered lecture modules on Mucositis, gastrointestinal physiology and the oral cavity, have been intimately involved in the re-work of Human Biology 1A/B, been appointed as a MBBS case-based learning tutor, and am a member of the Indigenous Tutor Assistance Scheme. To date, I have been involved in the following courses (in the Faculty of Health and Medical Sciences) as a tutor or project supervisor: Human Biology I, Essentials of Pathology III, Cellular and Systems Neurobiology III, Cells Tissues and Development II, Biology of Disease II, Investigative Cell Biology III, Comparative Reproductive Biology of Mammals III, Comparative Neuroanatomy III, Structural Cell Biology III.

My teaching has also been complimented by attendance of the 'BEST' Program: Becoming an Effective Supervisor and Teacher, a one-day Learning and Teaching course for Sessional Teachers, Tutors and Academic Staff of the Faculty of Health and Medical Sciences.

Online Education

In 2015, I was invited to take part in the production, editing and delivery of the University's first Massive Open Online Course (MOOC), delivered through EdX and organised by Prof Mario Ricci. In its first year, there were over 5000 students enrolled. I helped with the production of interactive elements of the course, as well as reviewing the course content. I am now involved in moderation of the discussion board. In line with these roles, I also produced a literature review on current e-Assessment strategies that have been implemented in medical/health related tertiary education. This has been identified as a key area for growth by the Vice Chancellor and will be reviewed by the board for e-Assessment within the University of Adelaide. In 2018, I have also been appointed as a UniSA Online Educator (Health Sciences Course) as part of their new UniSA Online Initiative which aims to provide an entire course online, thus targeting a new student demographic.

Current Higher Degree by Research Supervision (University of Adelaide)

Date	Role	Research Topic	Program	Degree Type	Student Load	Student Name
2022	Co-Supervisor	The CANnabinoids in CANcer Therapy (CANCAN) trial: using patient reported outcomes to assess gut distress	Master of Philosophy (Public Health)	Master	Full Time	Miss Katrina Cao
2022	Co-Supervisor	Modelling neurotoxicities following paediatric cancer treatments to improve cognitive outcomes and quality of survival	Doctor of Philosophy	Doctorate	Full Time	Miss Maya Rochelle Davies
2021	Co-Supervisor	Mechanisms of bortezomib-induced gut dysfunction and novel strategies to mitigate its impact in people with multiple myeloma.	Doctor of Philosophy	Doctorate	Full Time	Miss Jacqui Steele Scott
2019	Co-Supervisor	The Role of TLR4 in Response to Chemotherapy	Doctor of Philosophy	Doctorate	Full Time	Mrs Elise Ellen Crame
2019	Co-Supervisor	The microbiome-gut-brain axis in chemotherapy-induced cognitive impairment	Doctor of Philosophy	Doctorate	Full Time	Miss Courtney Brooke Subramaniam

Board Memberships

Date	Role	Board name	Institution name	Country
2018 - ongoing	Member	Information and Communication Committee	Multinational Association for Supportive Care in Cancer	Australia
2017 - ongoing	Co-Chair	Social Media Working Group	The Multinational Association for Supportive Care in Cancer
2016 - ongoing	Co-Chair	Mucositis Study Group - Guideline Developemnt	Multinational Association for Supportive Care in Cancer	Australia

Committee Memberships

Date	Role	Committee	Institution	Country
2021 - ongoing	Secretary	Consumer Engagement Committee	Multinational Association for Supportive Care in Cancer	Canada
2021 - ongoing	Member	Consumer Engagement Committee	Health Translation SA	Australia
2021 - ongoing	Co-Chair	Mucositis Study Group	Multinational Association for Supportive Care in Cancer	Canada
2020 - ongoing	Member	EMCR Committee	SAHMRI	Australia
2020 - ongoing	Co-Founder	Australasian Human Microbiome Network	AHMRN	Australia
2018 - ongoing	Member	Information and Communication	Multinational Association for Supportive Care in Cancer	United States
2017 - ongoing	Chair	Social Media Engagement (Mucositis Study Group)	Multinational Association for Supportive Care in Cancer	United States
2017 - ongoing	Co-Chair	Multinational Association for Supportive Care in Cancer: Update of the Clinical Practice Guidelines for Mucositis (Risk Prediction)
2016 - ongoing	Member	Multinational Association for Supportive Care in Cancer; Mucositis Study Group
2016 - ongoing	Member	Future Leaders Group
2016 - ongoing	Member	Australian Society for Medical Research
2015 - ongoing	Member	Neurological Complications Study Group	Multinational Association for Supportive Care in Cancer	Canada
2013 - ongoing	Representative	School of Medicine Board
2013 - ongoing	Representative	School of Medicine HDR Committee
2013 - 2016	Member	Health Sciences Postgraduate Association (HESPA)
2012 - ongoing	Member	Multinational Association for Supportive Care in Cancer
2012 - ongoing	Member	Golden Key International Honour Society

Position: NHMRC Externally-Funded Research Fellow B
Email: hannah.wardill@adelaide.edu.au
Campus: North Terrace
Building: SAHMRI, floor 7 South
Org Unit: Medical Sciences